BlackRock’s Acrivon Therapeutics ACRV Stock Holding History

BlackRock’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$290K	Buy	208,939 +3,815	+2%	+$6.66K	﹤0.01%	4660
2025 Q4	$494K	Sell	205,124 -125,833	-38%	-$274K	﹤0.01%	4486
2025 Q3	$599K	Sell	330,957 -76,665	-19%	-$108K	﹤0.01%	4416
2025 Q2	$485K	Sell	407,622 -531,085	-57%	-$729K	﹤0.01%	4452
2025 Q1	$1.91M	Sell	938,707 -6,789	-0.7%	-$36.6K	﹤0.01%	4013
2024 Q4	$5.69M	Buy	945,496 +158,514	+20%	+$1.15M	﹤0.01%	3668
2024 Q3	$5.51M	Buy	786,982 +19,962	+3%	+$157K	﹤0.01%	3660
2024 Q2	$4.45M	Buy	767,020 +23,119	+3%	+$186K	﹤0.01%	3726
2024 Q1	$5.32M	Buy	743,901 +178,069	+31%	+$827K	﹤0.01%	3645
2023 Q4	$2.78M	Buy	565,832 +37,072	+7%	+$196K	﹤0.01%	3911
2023 Q3	$5.05M	Sell	528,760 -4,595	-0.9%	-$53.1K	﹤0.01%	3659
2023 Q2	$6.91M	Buy	533,355 +59,128	+12%	+$716K	﹤0.01%	3583
2023 Q1	$6.02M	Buy	+474,227	New	+$7.96M	﹤0.01%	3556

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock's ACRV Position: Q1 2026 in Review

BlackRock increased its Acrivon Therapeutics (ACRV) stake by 1.9% in Q1 2026, buying an estimated $6.66K and bringing the position to 208,939 shares worth $290K. The position accounts for ﹤0.01% of the portfolio, ranked #4660.

BlackRock first reported a position in ACRV in Q1 2023 and has held it in 13 quarters since. The position peaked at $6.91M in Q2 2023. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

BlackRock held 208,939 shares of Acrivon Therapeutics worth $290K as of Q1 2026.
BlackRock bought 3,815 Acrivon Therapeutics shares in Q1 2026, an estimated $6.66K.
Acrivon Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4660 holding.
BlackRock first reported a position in Acrivon Therapeutics in Q1 2023 and has held it in 13 quarters since.
BlackRock's Acrivon Therapeutics position peaked at $6.91M in Q2 2023.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.